Metabolic disorders

Lisa Edelmann, Yaping Yang, Amy Yang, Ruth Kornreich

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Inborn errors of metabolism represent a highly diverse group of genetic disorders. Although individually the disorders are rare, collectively they are estimated to affect as many as 1 in 600 individuals. This chapter discusses the molecular mechanisms of disease and the available genetic testing for selected metabolic disorders. Mutations in many of the metabolic diseases are genetically heterogeneous and diagnoses are still widely dependent on biochemical testing. DNA testing is critical for confirmatory studies, genetic counseling, carrier and prenatal testing, and genotype-phenotype correlation, and is widely used for carrier screening for metabolic disorders in certain populations that have a high frequency of specific mutations due to founder effects. With increasing use of next-generation sequencing technologies in the clinical laboratory, DNA testing for confirmatory studies of all newborn screening positive results likely will be available in the near future.

Original languageEnglish (US)
Title of host publicationMolecular Pathology in Clinical Practice:Second Edition
PublisherSpringer International Publishing
Pages161-175
Number of pages15
ISBN (Electronic)9783319196749
ISBN (Print)9783319196732
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Founder Effect
Inborn Errors Metabolism
Inborn Genetic Diseases
DNA
Metabolic Diseases
Genetic Counseling
Genetic Testing
Genetic Association Studies
Mutation Rate
Heterozygote
Technology
Mutation
Population

Keywords

  • Andersen disease
  • Canavan disease
  • Cori disease
  • Galactosemia
  • Gaucher disease
  • Glycogen storage diseases
  • Hereditary fructose intolerance
  • Inborn errors of metabolism
  • Lysosomal storage disorders
  • Maple syrup urine disease
  • Medium-chain acyl coa dehydrogenase deficiency
  • Molecular testing
  • Newborn screening
  • Ornithine transcarbamylase deficiency
  • Phenylketonuria
  • Pompe disease
  • Tay-Sachs disease
  • Very-long-chain acyl-coa dehydrogenase deficiency
  • Von gierke disease
  • X-linked adrenoleukodystrophy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Edelmann, L., Yang, Y., Yang, A., & Kornreich, R. (2016). Metabolic disorders. In Molecular Pathology in Clinical Practice:Second Edition (pp. 161-175). Springer International Publishing. https://doi.org/10.1007/978-3-319-19674-9_11

Metabolic disorders. / Edelmann, Lisa; Yang, Yaping; Yang, Amy; Kornreich, Ruth.

Molecular Pathology in Clinical Practice:Second Edition. Springer International Publishing, 2016. p. 161-175.

Research output: Chapter in Book/Report/Conference proceedingChapter

Edelmann, L, Yang, Y, Yang, A & Kornreich, R 2016, Metabolic disorders. in Molecular Pathology in Clinical Practice:Second Edition. Springer International Publishing, pp. 161-175. https://doi.org/10.1007/978-3-319-19674-9_11
Edelmann L, Yang Y, Yang A, Kornreich R. Metabolic disorders. In Molecular Pathology in Clinical Practice:Second Edition. Springer International Publishing. 2016. p. 161-175 https://doi.org/10.1007/978-3-319-19674-9_11
Edelmann, Lisa ; Yang, Yaping ; Yang, Amy ; Kornreich, Ruth. / Metabolic disorders. Molecular Pathology in Clinical Practice:Second Edition. Springer International Publishing, 2016. pp. 161-175
@inbook{39fc8dc0dbf94c069e81ebe3fc347135,
title = "Metabolic disorders",
abstract = "Inborn errors of metabolism represent a highly diverse group of genetic disorders. Although individually the disorders are rare, collectively they are estimated to affect as many as 1 in 600 individuals. This chapter discusses the molecular mechanisms of disease and the available genetic testing for selected metabolic disorders. Mutations in many of the metabolic diseases are genetically heterogeneous and diagnoses are still widely dependent on biochemical testing. DNA testing is critical for confirmatory studies, genetic counseling, carrier and prenatal testing, and genotype-phenotype correlation, and is widely used for carrier screening for metabolic disorders in certain populations that have a high frequency of specific mutations due to founder effects. With increasing use of next-generation sequencing technologies in the clinical laboratory, DNA testing for confirmatory studies of all newborn screening positive results likely will be available in the near future.",
keywords = "Andersen disease, Canavan disease, Cori disease, Galactosemia, Gaucher disease, Glycogen storage diseases, Hereditary fructose intolerance, Inborn errors of metabolism, Lysosomal storage disorders, Maple syrup urine disease, Medium-chain acyl coa dehydrogenase deficiency, Molecular testing, Newborn screening, Ornithine transcarbamylase deficiency, Phenylketonuria, Pompe disease, Tay-Sachs disease, Very-long-chain acyl-coa dehydrogenase deficiency, Von gierke disease, X-linked adrenoleukodystrophy",
author = "Lisa Edelmann and Yaping Yang and Amy Yang and Ruth Kornreich",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-19674-9_11",
language = "English (US)",
isbn = "9783319196732",
pages = "161--175",
booktitle = "Molecular Pathology in Clinical Practice:Second Edition",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Metabolic disorders

AU - Edelmann, Lisa

AU - Yang, Yaping

AU - Yang, Amy

AU - Kornreich, Ruth

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Inborn errors of metabolism represent a highly diverse group of genetic disorders. Although individually the disorders are rare, collectively they are estimated to affect as many as 1 in 600 individuals. This chapter discusses the molecular mechanisms of disease and the available genetic testing for selected metabolic disorders. Mutations in many of the metabolic diseases are genetically heterogeneous and diagnoses are still widely dependent on biochemical testing. DNA testing is critical for confirmatory studies, genetic counseling, carrier and prenatal testing, and genotype-phenotype correlation, and is widely used for carrier screening for metabolic disorders in certain populations that have a high frequency of specific mutations due to founder effects. With increasing use of next-generation sequencing technologies in the clinical laboratory, DNA testing for confirmatory studies of all newborn screening positive results likely will be available in the near future.

AB - Inborn errors of metabolism represent a highly diverse group of genetic disorders. Although individually the disorders are rare, collectively they are estimated to affect as many as 1 in 600 individuals. This chapter discusses the molecular mechanisms of disease and the available genetic testing for selected metabolic disorders. Mutations in many of the metabolic diseases are genetically heterogeneous and diagnoses are still widely dependent on biochemical testing. DNA testing is critical for confirmatory studies, genetic counseling, carrier and prenatal testing, and genotype-phenotype correlation, and is widely used for carrier screening for metabolic disorders in certain populations that have a high frequency of specific mutations due to founder effects. With increasing use of next-generation sequencing technologies in the clinical laboratory, DNA testing for confirmatory studies of all newborn screening positive results likely will be available in the near future.

KW - Andersen disease

KW - Canavan disease

KW - Cori disease

KW - Galactosemia

KW - Gaucher disease

KW - Glycogen storage diseases

KW - Hereditary fructose intolerance

KW - Inborn errors of metabolism

KW - Lysosomal storage disorders

KW - Maple syrup urine disease

KW - Medium-chain acyl coa dehydrogenase deficiency

KW - Molecular testing

KW - Newborn screening

KW - Ornithine transcarbamylase deficiency

KW - Phenylketonuria

KW - Pompe disease

KW - Tay-Sachs disease

KW - Very-long-chain acyl-coa dehydrogenase deficiency

KW - Von gierke disease

KW - X-linked adrenoleukodystrophy

UR - http://www.scopus.com/inward/record.url?scp=85027492571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027492571&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-19674-9_11

DO - 10.1007/978-3-319-19674-9_11

M3 - Chapter

AN - SCOPUS:85027492571

SN - 9783319196732

SP - 161

EP - 175

BT - Molecular Pathology in Clinical Practice:Second Edition

PB - Springer International Publishing

ER -